Core Viewpoint - The company announced a change in the designated sponsor representatives for its ongoing supervision during the initial public offering on the Sci-Tech Innovation Board, ensuring continuity in oversight of the use of raised funds [1]. Group 1 - The company received a letter from Huatai United Securities regarding the replacement of the sponsor representative for the ongoing supervision of its IPO on June 27, 2025 [1]. - Due to a job change, the original sponsor representative, Mr. Hong Jie Chao, is unable to continue his duties, leading to the appointment of Mr. Wang Jie Qiu as his replacement [1]. - The current sponsor representatives for the company's IPO supervision are now Mr. Wang Jie Qiu and Mr. Li Hao [1]. Group 2 - The company expressed gratitude to Mr. Hong Jie Chao for his contributions during the IPO and ongoing supervision period [1]. - Mr. Wang Jie Qiu has extensive experience in investment banking, having participated in multiple IPOs and bond issuances since 2011 [2]. - His previous projects include IPOs for Fengshan Group, Pengyao Environmental Protection, and several others, indicating a strong background in the industry [2].
南京诺唯赞生物科技股份有限公司关于更换保荐代表人的公告